Dalbavancin: new single-dose antibiotic for acute skin infections

Xydalba (dalbavancin) is the first antibiotic to provide a full course of iv therapy for acute bacterial skin and skin structure infections in a single dose.

Dalbavancin is available as a powder for concentrate to be made up into a solution for infusion providing 20mg per ml.

The recommended adult dose is a single iv infusion of 1.5g given over 30 minutes or a single infusion of 1g followed by a 500mg dose one week later. Dalbavancin is not recommended in children and adolescents under 18 years of age.

Dalbavancin is a bactericidal lipoglycopeptide which demonstrates in vitro activity against Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus.

The most commonly reported adverse effects with dalbavancin in clinical trials were headache, nausea and diarrhoea.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases